207 related articles for article (PubMed ID: 35226736)
1. BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
Zaiken MC; Flynn R; Paz KG; Rhee SY; Jin S; Mohamed FA; Saha A; Thangavelu G; Park PMC; Hemming ML; Sage PT; Sharpe AH; DuPage M; Bluestone JA; Panoskaltsis-Mortari A; Cutler CS; Koreth J; Antin JH; Soiffer RJ; Ritz J; Luznik L; Maillard I; Hill GR; MacDonald KPA; Munn DH; Serody JS; Murphy WJ; Kean LS; Zhang Y; Bradner JE; Qi J; Blazar BR
Blood; 2022 May; 139(19):2983-2997. PubMed ID: 35226736
[TBL] [Abstract][Full Text] [Related]
2. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.
Flynn R; Du J; Veenstra RG; Reichenbach DK; Panoskaltsis-Mortari A; Taylor PA; Freeman GJ; Serody JS; Murphy WJ; Munn DH; Sarantopoulos S; Luznik L; Maillard I; Koreth J; Cutler C; Soiffer RJ; Antin JH; Ritz J; Dubovsky JA; Byrd JC; MacDonald KP; Hill GR; Blazar BR
Blood; 2014 Jun; 123(25):3988-98. PubMed ID: 24820310
[TBL] [Abstract][Full Text] [Related]
3. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.
Srinivasan M; Flynn R; Price A; Ranger A; Browning JL; Taylor PA; Ritz J; Antin JH; Murphy WJ; Luznik L; Shlomchik MJ; Panoskaltsis-Mortari A; Blazar BR
Blood; 2012 Feb; 119(6):1570-80. PubMed ID: 22072556
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.
Paz K; Flynn R; Du J; Qi J; Luznik L; Maillard I; MacDonald KP; Hill GR; Serody JS; Murphy WJ; Sage PT; Sharpe AH; Miklos D; Cutler CS; Koreth J; Antin JH; Soiffer RJ; Ritz J; Bradner JE; Melnick AM; Blazar BR
Blood; 2019 Jan; 133(1):94-99. PubMed ID: 30279226
[TBL] [Abstract][Full Text] [Related]
5. Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.
Paz K; Flynn R; Du J; Tannheimer S; Johnson AJ; Dong S; Stark AK; Okkenhaug K; Panoskaltsis-Mortari A; Sage PT; Sharpe AH; Luznik L; Ritz J; Soiffer RJ; Cutler CS; Koreth J; Antin JH; Miklos DB; MacDonald KP; Hill GR; Maillard I; Serody JS; Murphy WJ; Munn DH; Feser C; Zaiken M; Vanhaesebroeck B; Turka LA; Byrd JC; Blazar BR
Am J Transplant; 2019 Jun; 19(6):1820-1830. PubMed ID: 30748099
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.
Du J; Paz K; Flynn R; Vulic A; Robinson TM; Lineburg KE; Alexander KA; Meng J; Roy S; Panoskaltsis-Mortari A; Loschi M; Hill GR; Serody JS; Maillard I; Miklos D; Koreth J; Cutler CS; Antin JH; Ritz J; MacDonald KP; Schacker TW; Luznik L; Blazar BR
Blood; 2017 May; 129(18):2570-2580. PubMed ID: 28254742
[TBL] [Abstract][Full Text] [Related]
7. Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD.
Kolupaev OV; Dant TA; Bommiasamy H; Bruce DW; Fowler KA; Tilley SL; McKinnon KP; Sarantopoulos S; Blazar BR; Coghill JM; Serody JS
Blood Adv; 2018 Sep; 2(18):2307-2319. PubMed ID: 30228128
[TBL] [Abstract][Full Text] [Related]
8. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
[TBL] [Abstract][Full Text] [Related]
9. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.
Radojcic V; Paz K; Chung J; Du J; Perkey ET; Flynn R; Ivcevic S; Zaiken M; Friedman A; Yan M; Pletneva MA; Sarantopoulos S; Siebel CW; Blazar BR; Maillard I
Blood; 2018 Nov; 132(20):2188-2200. PubMed ID: 30181175
[TBL] [Abstract][Full Text] [Related]
10. Ezh2-mediated epigenetic modification is required for allogeneic T cell-induced lupus disease.
Zhen Y; Smith RD; Finkelman FD; Shao WH
Arthritis Res Ther; 2020 Jun; 22(1):133. PubMed ID: 32503684
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice.
Wu Y; Schutt S; Paz K; Zhang M; Flynn RP; Bastian D; Sofi MH; Nguyen H; Dai M; Liu C; Chang YJ; Blazar BR; Yu XZ
Blood; 2018 Apr; 131(17):1974-1986. PubMed ID: 29530952
[TBL] [Abstract][Full Text] [Related]
12. Zaiken MC, Flynn R, Paz KG, et al. BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022;139(19):2983-2997.
Blood; 2023 Oct; 142(16):1405. PubMed ID: 37856091
[No Abstract] [Full Text] [Related]
13. Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease.
Shao L; Lie AK; Zhang Y; Wong CH; Kwong YL
Ann Hematol; 2015 Sep; 94(9):1493-504. PubMed ID: 25963280
[TBL] [Abstract][Full Text] [Related]
14. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.
Flynn R; Allen JL; Luznik L; MacDonald KP; Paz K; Alexander KA; Vulic A; Du J; Panoskaltsis-Mortari A; Taylor PA; Poe JC; Serody JS; Murphy WJ; Hill GR; Maillard I; Koreth J; Cutler CS; Soiffer RJ; Antin JH; Ritz J; Chao NJ; Clynes RA; Sarantopoulos S; Blazar BR
Blood; 2015 Jun; 125(26):4085-94. PubMed ID: 25852057
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease.
Thangavelu G; Zaiken MC; Mohamed FA; Flynn R; Du J; Rhee SY; Riddle MJ; Aguilar EG; Panoskaltsis-Mortari A; Sanders ME; Blazar BR
Front Immunol; 2022; 13():765319. PubMed ID: 35359939
[TBL] [Abstract][Full Text] [Related]
16. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
Genta S; Pirosa MC; Stathis A
Curr Oncol Rep; 2019 Feb; 21(2):13. PubMed ID: 30715616
[TBL] [Abstract][Full Text] [Related]
17. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
Flynn R; Paz K; Du J; Reichenbach DK; Taylor PA; Panoskaltsis-Mortari A; Vulic A; Luznik L; MacDonald KK; Hill GR; Nyuydzefe MS; Weiss JM; Chen W; Trzeciak A; Serody JS; Aguilar EG; Murphy WJ; Maillard I; Munn D; Koreth J; Cutler CS; Antin JH; Ritz J; Waksal SD; Zanin-Zhorov A; Blazar BR
Blood; 2016 Apr; 127(17):2144-54. PubMed ID: 26983850
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the IRE-1α/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice.
Schutt SD; Wu Y; Tang CH; Bastian D; Nguyen H; Sofi MH; Zhang M; Liu C; Helke K; Wilson C; Schnapp LM; Del Valle JR; Hu CC; Yu XZ
Blood Adv; 2018 Feb; 2(4):414-427. PubMed ID: 29483082
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
Dubovsky JA; Flynn R; Du J; Harrington BK; Zhong Y; Kaffenberger B; Yang C; Towns WH; Lehman A; Johnson AJ; Muthusamy N; Devine SM; Jaglowski S; Serody JS; Murphy WJ; Munn DH; Luznik L; Hill GR; Wong HK; MacDonald KK; Maillard I; Koreth J; Elias L; Cutler C; Soiffer RJ; Antin JH; Ritz J; Panoskaltsis-Mortari A; Byrd JC; Blazar BR
J Clin Invest; 2014 Nov; 124(11):4867-76. PubMed ID: 25271622
[TBL] [Abstract][Full Text] [Related]
20. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
